News

April 21, 2023
Sernova Reminds Shareholders to Vote FOR the Eight Management Director Nominees Using ONLY the WHITE Management Proxy

April 18, 2023
Two Independent Proxy Advisory Firms, Including Glass Lewis & Co. LLC. Recommend Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy

April 14, 2023
Institutional Shareholder Services Inc. Recommends Sernova’s Shareholders Vote FOR all Management Nominees on Management’s White Proxy

April 10, 2023
Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med

April 6, 2023
Sernova Responds to Dissident Shareholders’ Misleading Statements and Provides Corporate Updates

March 22, 2023
Sernova Announces Abstract on First Cohort of its Phase 1/2 Study Involving Islet Allotransplantation into Pre-vascularized Cell Pouch™ Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions 2023

March 14, 2023
Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit

March 8, 2023
Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes

March 2, 2023
Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences

January 30, 2023
Sernova Announces Advancements with its Novel Cell Pouch SystemTM to Preserve Thyroid Function Following Total Thyroidectomy

IR Contact


David Burke
Vice President, Investor Relations
917.751.5713
david.burke@sernova.com

Email Alerts Sign-Up

Scroll to Top